BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26029931)

  • 21. Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype.
    Jarvis EM; Kirk JA; Clarke CL
    Cancer Genet Cytogenet; 1998 Mar; 101(2):109-15. PubMed ID: 9494611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kriege M; Jager A; Hooning MJ; Huijskens E; Blom J; van Deurzen CH; Bontenbal M; Collee JM; Menke-Pluijmers MB; Martens JW; Seynaeve C
    Cancer; 2012 Feb; 118(4):899-907. PubMed ID: 21761396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 mutation influences progesterone response in human benign mammary organoids.
    Davaadelger B; Choi MR; Singhal H; Clare SE; Khan SA; Kim JJ
    Breast Cancer Res; 2019 Nov; 21(1):124. PubMed ID: 31771627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid hormone receptor-specific interactions with steroid receptor coactivator-1 in the pituitary.
    Sadow PM; Koo E; Chassande O; Gauthier K; Samarut J; Xu J; O'Malley BW; Seo H; Murata Y; Weiss RE
    Mol Endocrinol; 2003 May; 17(5):882-94. PubMed ID: 12576486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas.
    Aghmesheh M; Edwards L; Clarke CL; Byth K; Katzenellenbogen BS; Russell PJ; Friedlander M; Tucker KM; de Fazio A
    Gynecol Oncol; 2005 Apr; 97(1):16-25. PubMed ID: 15790432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of BRCA1 protein in breast cancer and its prognostic significance.
    Rakha EA; El-Sheikh SE; Kandil MA; El-Sayed ME; Green AR; Ellis IO
    Hum Pathol; 2008 Jun; 39(6):857-65. PubMed ID: 18400253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis.
    Furumoto H; Ying H; Chandramouli GV; Zhao L; Walker RL; Meltzer PS; Willingham MC; Cheng SY
    Mol Cell Biol; 2005 Jan; 25(1):124-35. PubMed ID: 15601836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer.
    Bolf EL; Gillis NE; Barnum MS; Beaudet CM; Yu GY; Tomczak JA; Stein JL; Lian JB; Stein GS; Carr FE
    Horm Cancer; 2020 Feb; 11(1):34-41. PubMed ID: 31865591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs.
    Chan IH; Privalsky ML
    Oncogene; 2006 Jun; 25(25):3576-88. PubMed ID: 16434963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
    Ashraf M; Jha JK; Mukherjee N; Panda CK; Nayak S; Jadhav TS; Dikshit N; Nath NC; Chakraborty J; Biswas J
    J Indian Med Assoc; 2011 Dec; 109(12):873-8. PubMed ID: 23469566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic and muscle expression of thyroid hormone receptors in association with body and muscle growth in large yellow croaker, Pseudosciaena crocea (Richardson).
    Yang X; Xie J; Wu T; Yue G; Chen J; Zhao R
    Gen Comp Endocrinol; 2007 Apr; 151(2):163-71. PubMed ID: 17324424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers.
    King TA; Gemignani ML; Li W; Giri DD; Panageas KS; Bogomolniy F; Arroyo C; Olvera N; Robson ME; Offit K; Borgen PI; Boyd J
    Cancer Res; 2004 Aug; 64(15):5051-3. PubMed ID: 15289302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 expression in triple negative sporadic breast cancers.
    Galizia E; Giorgetti G; Piccinini G; Santinelli A; Loretelli C; Bianchi F; Gagliardini D; Carbonari G; Pisa E; Belvederesi L; Bracci R; Ferretti C; Corradini F; Cellerino R
    Anal Quant Cytol Histol; 2010 Feb; 32(1):24-9. PubMed ID: 20701084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
    Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
    BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
    Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
    Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones.
    Lee EY
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):68-73. PubMed ID: 18197009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.